SCHEMBL4505014

SCHEMBL4505014

O=C(c1ccc(O)cc1)N1Cc2ccc(Br)cc2C1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ABHD6 Q9BV23 1/20 0.48
HPGD P15428 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA7 P43166 1/20 0.47
CA9 Q16790 1/20 0.47
CA14 Q9ULX7 1/20 0.47
TRAP1 Q12931 4/20 0.47
HSP90B1 P14625 4/20 0.47
DPP8 Q6V1X1 1/20 0.46
DPP9 Q86TI2 1/20 0.46
DPP7 Q9UHL4 1/20 0.46
NAMPT P43490 3/20 0.45
HSP90AA1 P07900 7/20 0.44
HSP90AB1 P08238 5/20 0.44
POLB P06746 1/20 0.43
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24503136 0.86 TRAP1 (0.53) ABHD6HPGDTRAP1HSP90B1DPP8
SCHEMBL26525246 0.82 GPR183 (0.51) ABHD6HPGDDPP8DPP9DPP7
SCHEMBL21768167 0.81 MAOB (0.56) HPGDCA1CA2CA7CA9
SCHEMBL30089453 0.81 MAOB (0.56) HPGDCA1CA2CA7CA9
SCHEMBL1304055 0.80 HSP90B1 (0.63) HPGDCA1CA2CA7CA9
SCHEMBL4437450 0.76 ABHD6 (0.55) ABHD6DPP8DPP9DPP7NAMPT
SCHEMBL1956852 0.76 ABHD6 (0.55) ABHD6DPP8DPP9DPP7NAMPT
SCHEMBL24503025 0.76 ABHD6 (0.54) ABHD6HPGDCA1CA2CA7
SCHEMBL5518906 0.75 CA1 (0.67) HPGDCA1CA2CA7CA9
SCHEMBL5512748 0.75 CA1 (0.76) HPGDCA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101230033-B New azabicycloalkane derivatives, preparing method and medicament combination containing the same SERVIER LAB 2011-03-09 CN disclosed
CN-100577160-C Novel azabicyclo derivatives, preparation method thereof and pharmaceutical compositions containing same SERVIER LAB 2010-01-06 CN disclosed
US-7576120-B2 Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2009-08-18 US disclosed
CN-101230033-A New azabicycloalkane derivatives, preparing method and medicament combination containing the same SERVIER LAB (FR) 2008-07-30 CN disclosed
EP-1720544-B1 NOVEL AZABICYCLIC DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SERVIER LAB (FR) 2008-03-19 EP disclosed
US-20070197625-A1 Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them. LES LABORATORATIES SERVIER (FR) 2007-08-23 US disclosed
CN-1921848-A Novel azabicyclo derivatives, preparation method thereof and pharmaceutical compositions containing same SERVIER LAB (FR) 2007-02-28 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197625-A1 Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them. HRH2, HNMT, HRH1 ABHD6 2946/4885HPGD 443/4885CA1 1460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.